In this episode, Joe interviews Maya Albert: Co-Founder of the Psyched conference, and Director of Operations at Tabula Rasa Ventures and the Synthesis Institute. She shares her journey of how she became involved in the psychedelic space through her mother, and her personal experience as a patient in a clinical trial on psilocybin for the […]

The post PT430 – Psychedelics for Eating Disorders, Davos’ House of Psychedelics, and The Future of the Synthesis Institute appeared first on Psychedelics Today.

Previous articleFILAMENT HEALTH ANNOUNCES FDA APPROVAL OF TWO CLINICAL TRIALS STUDYING ITS BOTANICAL PSILOCYBIN DRUG CANDIDATE PEX010
Next articleatai Life Sciences Announces Results from the Phase 1 IV-to-Subcutaneous Bridging Study of PCN-101 (R-Ketamine)